🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07145515
Recruiting Not applicable

Enhancing Heart Allograft Function With the OCS Heart System Trial

NCT07145515 · tracked via the Priya Life Science USA tracker
Sponsor
TransMedics
Phase
Not applicable
Started
2026-01
Last updated
2026-01-12

Condition(s) studied

Heart Transplant

Investigational drug(s) / intervention(s)

OCS HeartStatic Cold Storage (SCS)

OCS Heart: Preservation of donor hearts with OCS Heart System and novel OCS Solution and OCS Functional Enhancer.

Static Cold Storage (SCS): Preservation of donor hearts with static cold storage.

Study summary

This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In addition, this trial will evaluate the performance of the novel OCS Solution and OFE compared to Static Cold Storage (SCS) in DBD heart transplantation to potentially demonstrate superiority.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Part A - DCD Donor Hearts \& DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications): Donor Inclusion Criteria * Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room. * All DCD donors eligible for functional warm ischemic time criteria ≤ 30 minutes. WIT defined as time from when mean systolic blood pressure (SBP) is \<50mmHg (sustained for at least 5 minutes) to aortic cross clamp and administration of old cardioplegia in the donor. * DBD donor hearts with an expected cross clamp of ≥ 4 hours * DBD donor hearts with any of the following organ quality concerns, regardless of cross clamp time: * Donor age ≥ 40 years old * Unknown downtime * Insignificant CAD * LVEF ≤ 50% Donor Exclusion • Moderate to severe aortic incompetence Part B - DBD Donor Hearts Currently Used with Cold Storage (New Indication): Donor Inclusion Criteria * Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room. * Eligible for randomization to OCS or SCS treatment arms. * DBD donor hearts with an expected cross clamp time of \< 4 hours. Donor Exclusion * Moderate to severe aortic incompetence * DBD donor with any of the following organ quality concerns: * Donor age ≥ 40 years old * Unknown downtime * Insignificant CAD * LVEF ≤ 50% Recipient Eligibility Criteria (for Part A and B Cohorts) Inclusion * Signed informed consent document and authorization to use and disclose protected health information * Heart transplant candidate * Age ≥ 18 years old Exclusion • Participant in any other interventional clinical or investigational trials/programs that may confound the outcomes of this trial

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
University of California San Francisco San Francisco California Recruiting
Tampa General Hospital Tampa Florida Recruiting
Massachusetts General Hospital Boston Massachusetts Recruiting
Mount Sinai New York New York Recruiting
Columbia University Irving Medical Center/ New York Presbyterian Hospital New York New York Not Yet Recruiting
Westchester Medical Center Valhalla New York Recruiting
Duke University Durham North Carolina Recruiting
Baylor Scott and White Dallas Texas Recruiting

More TransMedics trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07145515 on ClinicalTrials.gov ↗ ← All trials in the USA